Search

Hutchison China MediTech Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

14.3 5.22

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

13.5

Max

14.31

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-8.9M

-8M

Pardavimai

3.7M

139M

P/E

Sektoriaus vid.

136.6

56.432

Pelno marža

-5.724

Darbuotojai

1,790

EBITDA

18M

4M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+23.14% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

462M

2.4B

Ankstesnė atidarymo kaina

9.08

Ankstesnė uždarymo kaina

14.3

Naujienos nuotaikos

By Acuity

50%

50%

106 / 339 reitingas Healthcare

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-20 04:01; UTC

News

Ethereum is declining, reversing four sessions of gains, with a cumulative return of -2.04% since Saturday amid ongoing geopolitical instability affecting markets.

2026-09-20 04:01; UTC

News

Ethereum is declining, reversing four sessions of gains, amid ongoing geopolitical instability related to the Middle East conflict affecting energy prices and markets.

2026-09-20 02:51; UTC

News

Bitcoin is modestly lower, continuing a trend since Saturday, as the People's Bank of China maintains its one-year Loan Prime Rate at 3.00%.

2026-09-20 02:51; UTC

News

Bitcoin is modestly lower, continuing a trend since Saturday's close, as the People's Bank of China maintains its one-year Loan Prime Rate at 3.00%.

2026-09-19 00:06; UTC

News

Hf Foods Group Inc. has terminated its $100 million equity offering program, with the stock declining in after-market trading following this decision.

2026-09-19 00:02; UTC

News

Block Inc is facilitating Ideal Nutrition's expansion to at least 20 U.S. locations, contributing to a modest increase in its stock during after-market hours.

2026-09-19 00:02; UTC

News
Social Media

MongoDB reported after-market earnings of $771.77 million and EPS of $1.90, exceeding estimates, with stock trading higher in line with market trends.

2026-09-19 00:02; UTC

News
Social Media

Accenture PLC and Anthropic announced a partnership to invest $1 billion each in AI safety, driving a significant increase in Accenture's stock price in after-hours trading.

2026-09-19 00:02; UTC

News

Shares lower in after-market as DOJ reviews antitrust lawsuit.

2026-09-19 00:02; UTC

News
Correlated Moves

Corning Inc's stock is modestly lower in after-market trading, potentially influenced by ASML Holding, despite four consecutive higher daily closes leading into this session.

2026-09-19 00:02; UTC

News

Kimberly-Clark Corp is higher in after-market trading following plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns.

2026-09-19 00:01; UTC

News

S&P Global Inc is experiencing modest gains in after-market trading, recovering from an early dip while remaining below its 20-day moving average.

2026-09-19 00:01; UTC

News

RTX Corp is seeing a modest decline in after-market trading, continuing a downward trend since Friday's close and remaining below its 20-day moving average.

2026-09-19 00:01; UTC

News

Union Pacific Corp shares are trading lower in after-market hours, despite UBS upgrading its rating to Buy and raising the price target to $339.

2026-09-18 23:41; UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

2026-09-18 23:31; UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

2026-09-18 23:26; UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

2026-09-18 23:16; UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

2026-09-18 23:11; UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

2026-09-18 23:11; UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

2026-09-18 23:06; UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

2026-09-18 23:06; UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

2026-09-18 23:06; UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

2026-09-18 23:06; UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

2026-09-18 23:06; UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

2026-09-18 23:06; UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

2026-09-18 23:06; UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

2026-09-18 23:06; UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

2026-09-18 23:06; UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

2026-09-18 23:01; UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

23.14% į viršų

12 mėnesių prognozė

Vidutinis 16.833 USD  23.14%

Aukščiausias 18.5 USD

Žemiausias 14 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

2

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

106 / 339 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.